Compare Cytokinetics Inc (CYTK) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while YieldMax NVDA Option Income Strategy ETF trades at $12.57 (market cap $1.45B). The key difference: Cytokinetics Inc is far larger — about 5.9× YieldMax NVDA Option Income Strategy ETF's market cap, and Cytokinetics Inc is more actively traded (2,594,626 versus 1,943,739). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| CYTK | NVDY | |
|---|---|---|
Market Cap | $8.62B | $1.45B |
Volume | 2,594,626 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $87.26 | $17.21 |
52-Week Low | $54.76 | $11.58 |
Typical Hold Time | 19 Days | 43 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.62, down 3.0% today amid bearish technical signals. The ETF generates income through covered calls on NVIDIA stock but faces structural limitations on upside participation. Recent analyst commentary highlights concerns about NAV erosion despite the attractive 39.7% annualized distribution rate. Technical indicators show bearish momentum with support at $12 and resistance at $13.
The outlook remains cautious as declining NVIDIA volatility reduces option income potential. While weekly distributions provide income, the capped upside and NAV erosion present significant risks for long-term investors. Analyst consensus leans toward Hold ratings, suggesting limited growth prospects despite strong underlying NVIDIA fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
